Marco Meglio
Editor at NeurologyLive
Host at NeurologyLive Mind Moments
Editor, @Neurology_Live 🧠| Hofstra Alum | Views are my own | 📧[email protected] | bagel and basketball enthusiast
Articles
-
1 week ago |
neurologylive.com | Marco Meglio
Helius Medical Technologies recently announced Aetna as the latest healthcare payer to provide coverage costs for the company’s Portable Neuromodulation Stimulator (PoNS) device, a non-implantable, orally applied therapy used to improve balance and gait in patients with multiple sclerosis (MS).
-
1 week ago |
cgtlive.com | Rajesh Pahwa |Marco Meglio
This interview originally appeared on our sister site, NeurologyLive®. Episode 143 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
-
1 week ago |
neurologylive.com | Marco Meglio
Newly announced data from the phase 3 TEMPLE trial, a head-to-head study comparing atogepant (Qulipta; AbbVie) to topiramate (Topamax), 2 FDA-approved migraine medications, showed that atogepant met its primary end point, outperforming the anticonvulsant medication in both efficacy and safety measures.1 In this multicenter, double-blind, active-controlled trial, 545 patients with episodic or chronic migraine were randomly assigned to either atogepant or topiramate for a 24-week treatment...
-
1 week ago |
neurologylive.com | Marco Meglio
According to a recent announcement, the FDA has accepted Centessa Pharmaceuticals’ investigational new drug application (IND) for ORX142, an investigational orexin receptor 2 agonist (OX2R), to be tested in a phase 1 clinical study of healthy volunteers.1ORX142, which is being studied as a treatment for a select neurological and neurodegenerative disorders, will have its safety, tolerability, and pharmacokinetics evaluated in the phase 1 study.
-
1 week ago |
neurologylive.com | Marco Meglio
Increased plasma CLEC11A and SERPINA1 levels correlate with higher NMOSD risk, while elevated PF4V1 and FAM3B levels are linked to reduced risk. The study utilized 132 NMOSD patients and 1244 controls, applying the 2006 Wingerchuk diagnostic criteria for analysis. Sensitivity analyses confirmed no reverse causation, and drug target screening identified SERPINA1, CP, and TF as potential therapeutic targets.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 679
- Tweets
- 3K
- DMs Open
- No
RT @fabnascimen: A must-attend session on refractory #status! #EEG #epilepsy @IlaeWeb @yesILAE @WashUNeurology https://t.co/4vwtNpPsSf ht…
RT @BaptistHealthSF: 💡Great insights from Dr. Seif Elbualy on the expanding role of non-surgical interventional pain mgmt including percuta…
RT @LEAD_Coalition: #DownSyndrome and #Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress https://t.co/jL7ZTpz6Ih by @marc…
